Ernexa Therapeutics Inc. (ERNAW) Capital expenditures 2016–2025
Ernexa Therapeutics Inc. (ERNAW) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$37,000FY2025 · since FY2016: $427,000 → $37,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $37,000 | -90.0% |
| FY2024 | $369,000 | +1842.1% |
| FY2023 | $19,000 | -93.6% |
| FY2022 | $297,000 | +92.9% |
| FY2021 | $154,000 | +294.9% |
| FY2020 | $39,000 | -69.5% |
| FY2019 | $128,000 | -80.2% |
| FY2018 | $648,000 | -11.0% |
| FY2017 | $728,000 | +70.5% |
| FY2016 | $427,000 | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net incomeERNAW Net marginERNAW Gross profitERNAW Gross marginERNAW Operating incomeERNAW Operating marginERNAW Operating cash flowERNAW Free cash flowERNAW Return on equityERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Total liabilitiesERNAW Shareholders’ equityERNAW overview →